<SEC-DOCUMENT>0001650664-24-000120.txt : 20241104
<SEC-HEADER>0001650664-24-000120.hdr.sgml : 20241104
<ACCEPTANCE-DATETIME>20241104073330
ACCESSION NUMBER:		0001650664-24-000120
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241104
DATE AS OF CHANGE:		20241104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Editas Medicine, Inc.
		CENTRAL INDEX KEY:			0001650664
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464097528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37687
		FILM NUMBER:		241420762

	BUSINESS ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-401-9000

	MAIL ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>edit-20241104.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4fa94c25-92ef-46a9-adf4-220335ddf022,g:59548894-11c8-44cc-a232-aa68c1c17873,d:921a557154ed4a9b9844080a9450d4a7-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>edit-20241104</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="edit-20241104.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-04</xbrli:startDate><xbrli:endDate>2024-11-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i921a557154ed4a9b9844080a9450d4a7_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of The Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November&#160;4, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Editas Medicine, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:39.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37687</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-4097528</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">11 Hurley Street</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Cambridge,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02141</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">401-9000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EDIT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i921a557154ed4a9b9844080a9450d4a7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2024, Editas Medicine, Inc. (the &#8220;Company&#8221;) issued a press release announcing financial results for the fiscal quarter ended September 30, 2024 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;Filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i921a557154ed4a9b9844080a9450d4a7_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="editasmedicinepressrelease.htm">Press release issued by the Company on November 4, 2024*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.5pt">This exhibit shall be deemed to be furnished and not filed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i921a557154ed4a9b9844080a9450d4a7_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EDITAS MEDICINE, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 4, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Erick Lucera</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Erick Lucera</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>editasmedicinepressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i893750d952b9491c8cf794ead541ae95_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><img alt="image_0.jpg" src="image_0.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:162px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Editas Medicine Announces Third Quarter 2024 Results and Business Updates</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Achieved </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> preclinical proof of concept of HBG1&#47;2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine&#8217;s proprietary targeted LNP in a key step to developing a novel </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> treatment for sickle cell disease and beta thalassemia</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Company to provide an update on its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> progress and pipeline development in 1Q 2025</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI and the retained portions of the payments payable under the license agreement with Vertex, to fund operating expenses and capital expenditures into the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">second quarter of 2026</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CAMBRIDGE, Mass., November&#160;4, 2024 &#8211; Editas Medicine, Inc. (Nasdaq&#58; EDIT), a clinical-stage gene editing company, today reported financial results for the third quarter 2024 and provided business updates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;Achieving preclinical proof of concept of HBG1&#47;2 editing in HSPCs using our proprietary targeted  LNP, puts us on a clear path to develop a potentially first- and best-in-class </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">gene edited medicine for the treatment of sickle cell disease and beta thalassemia,&#8221; commented Gilmore O&#8217;Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. &#8220;As we continue our process to partner or out-license reni-cel, we also look forward to sharing a substantial clinical update from the RUBY trial of reni-cel, a potentially best-in-class cell therapy for the treatment of sickle cell disease, at ASH in December.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;I am proud of the Editas team&#8217;s work and our advancement in 2024 as we move closer to achieving our vision of becoming a leader in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> programmable gene editing medicine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">,&#8221; added Dr. O&#8217;Neill.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Recent Achievements and Outlook</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Ex Vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Hemoglobinopathies</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Reni-cel (renizgamglogene autogedtemcel, previously EDIT-301) Partnering&#47;Out-licensing</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.25pt">The Company has engaged Moelis &#38; Company LLC, a leading global independent investment bank, to lead the global process to partner or out-license reni-cel.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Reni-cel for Severe Sickle Cell Disease (SCD)</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">The Company will present a substantive RUBY clinical trial update of 28 patients with considerable clinical follow-up at the American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024. </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">Dataset will include safety data and efficacy data, including hematology parameters, vaso-occlusive events (VOEs), and patient reported outcomes (PROs).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">The Company continues to dose adult patients in the RUBY trial and has dosed 28 patients to date.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">The Company continues to manufacture drug product for the initial adolescent cohort patients and schedule dosing. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">As previously announced, the Company has completed enrollment of the adult and adolescent cohorts of the Phase 1&#47;2&#47;3 RUBY trial for SCD.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Reni-cel for Transfusion-dependent Beta Thalassemia (TDT)</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">The Company is on-track to present additional clinical data from the EdiTHAL trial by year-end 2024.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">As previously announced, the Company completed enrollment of the adult cohort of the EdiTHAL trial for TDT and continues to dose patients.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">In Vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Medicines</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:13.8pt">In vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Preclinical Proof of Concept Achieved&#58; Hematopoietic Stem and Progenitor Cell (HSPC) Editing</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">As disclosed on October 22, the Company established </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> preclinical proof of concept for the development of an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">medicine for sickle cell disease and beta thalassemia by demonstrating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> hematopoietic stem and progenitor cell (HSPC) editing of HBG1&#47;2 promoter utilizing a novel, Editas-proprietary targeted lipid nanoparticle (tLNP) for extrahepatic tissue delivery in a humanized mouse model (mice engrafted with human hematopoietic stem cells).  </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">The Company will provide an update on its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">progress and pipeline development in 1Q 2025. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">The Company continues to pursue an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> strategy and approach aimed at driving functional upregulation of gene expression to address loss of function or deleterious mutations.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Additional </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Targets</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.75pt">Editas Medicine and G</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">enevant Sciences entered into a collaboration and nonexclusive license agreement to combine Editas&#8217; CRISPR Cas12a genome editing systems with Genevant&#8217;s proprietary LNP technology in the development of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> gene editing medicines directed to functional upregulation of two liver targets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Business Development</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:14.15pt">On October 3, 2024, Editas Medicine announced the sale of certain future license fees and other payments owed to the Company under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million. The upfront cash payment brings non-dilutive capital to Editas Medicine, helping enable further pipeline development and related strategic priorities.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.53pt">The Company ended the third quarter 2024 with approximately $265.1&#160;million of cash, cash equivalents, and marketable securities, or approximately $322.1 million following receipt of the upfront cash payment from DRI. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Third Quarter 2024 Financial Results</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">September&#160;30, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, were </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$265.1&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> compared to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$318.3&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">June 30, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI and the </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">retained portions of the payments payable under the license agreement with Vertex, to fund operating expenses and capital expenditures into the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">second quarter of 2026</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Third Quarter 2024</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">For the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">three months ended September 30, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, net loss attributable to common stockholders was </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$62.1&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$0.75</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> per share, compared to net loss of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$45.0&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$0.55</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> per share, for the same period in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Collaboration and other research and development revenues </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">decreased</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$0.1&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">three months ended September 30, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, compared to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5.3&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the same period in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The decrease is primarily attributable to the receipt in the 2023 period of the upfront payment for the non-exclusive license to Vor Bio.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Research and development expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increased</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7.1&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$47.6&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">three months ended September 30, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, compared to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$40.5&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for the same period in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The increase is primarily related to clinical and manufacturing costs related to the accelerated progression of the Company&#8217;s reni-cel program as well as costs attributable to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> research and discovery.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">General and administrative expenses increased by $3.1&#160;million to $18.1&#160;million for the three months ended September 30, 2024, compared to $15.0&#160;million for the same period in 2023. The increase is primarily attributable to increased employee-related expenses related to increased headcount to support business operations due to the progression of reni-cel program.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Upcoming Events </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Editas Medicine plans to participate in the following scientific and medical conference&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">American Society of Hematology (ASH) Annual Meeting and Exposition</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">December 7-10, 2024</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">San Diego, CA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Editas Medicine plans to participate in the following investor events&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Guggenheim's Inaugural Healthcare Innovation Conference</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">November 12, 2024</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Boston, MA </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Stifel 2024 Healthcare Conference</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">November 19, 2024</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">New York, NY</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">7th Annual Evercore ISI HealthCONx Conference</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">December 3, 2024</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Coral Gables, FL</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">No 3Q Conference Call</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company is not hosting a conference call this quarter given it recently held a Strategic Update Webinar on October 22, 2024. A replay of the webinar is available in the Investors section of the Editas Medicine website at https&#58;&#47;&#47;ir.editasmedicine.com&#47;events-and-presentations. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About Editas Medicine</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR&#47;Cas12a and CRISPR&#47;Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute&#8217;s Cas12a patent estate and Broad Institute and Harvard University&#8217;s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8216;&#8216;anticipate,&#8217;&#8217; &#8216;&#8216;believe,&#8217;&#8217; &#8216;&#8216;continue,&#8217;&#8217; &#8216;&#8216;could,&#8217;&#8217; &#8216;&#8216;estimate,&#8217;&#8217; &#8216;&#8216;expect,&#8217;&#8217; &#8216;&#8216;intend,&#8217;&#8217; &#8216;&#8216;may,&#8217;&#8217; &#8216;&#8216;plan,&#8217;&#8217; &#8216;&#8216;potential,&#8217;&#8217; &#8216;&#8216;predict,&#8217;&#8217; &#8216;&#8216;project,&#8217;&#8217; &#8216;&#8216;target,&#8217;&#8217; &#8216;&#8216;should,&#8217;&#8217; &#8216;&#8216;would,&#8217;&#8217; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company&#8217;s intent to partner or out-license reni-cel and any benefits resulting therefrom, the initiation, timing, progress and results of the Company&#8217;s preclinical and clinical studies and its research and development programs, the timing for the Company&#8217;s receipt and presentation of data from its clinical trials and preclinical studies, including providing an update on its </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> progress and pipeline development in the first quarter of 2025 and presenting additional clinical data from the RUBY trial at the ASH Annual Meeting and Exposition and from the EdiTHAL trial by year-end 2024, the potential of, and expectations for, the Company&#8217;s product candidates, including any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> gene edited medicines the Company may develop, the timing or likelihood of regulatory filings and approvals, and the Company&#8217;s expectations regarding cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including&#58; uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials, including the RUBY and EdiTHAL trials, and clinical development of the Company&#8217;s product candidates, including reni-cel&#59; availability and timing of results from pre-clinical studies and clinical trials&#59; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials&#59; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company&#8217;s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption &#8220;Risk Factors&#8221; included in the Company&#8217;s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company&#8217;s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company&#8217;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i893750d952b9491c8cf794ead541ae95_4"></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EDITAS MEDICINE, INC.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Consolidated Statement of Operations</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">(amounts in thousands, except share and per share data)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collaboration and other research and development revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,336&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,710&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18,074&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47,639&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40,512&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">150,636&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">108,095&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18,088&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14,987&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55,633&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55,198&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65,727&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55,499&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">206,269&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">163,293&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(65,666)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(50,163)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(204,559)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(145,219)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other income, net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1,590)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3,530&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12,861&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12,464&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3,525&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,144&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12,861&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10,874&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(62,141)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(45,019)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(191,698)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(134,345)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(0.75)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(0.55)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2.33)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1.81)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82,485,199&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81,648,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82,245,679&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74,029,645&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i893750d952b9491c8cf794ead541ae95_7"></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">EDITAS MEDICINE, INC.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Selected Consolidated Balance Sheet Items</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">(amounts in thousands)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">September 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">265,088&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">427,135&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Working capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">198,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">277,612&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">327,567&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">499,153</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54,204&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60,667</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">175,634&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">349,097</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">###</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Media and Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">Cristi Barnett</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(617) 401-0113</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">cristi.barnett&#64;editasmed.com</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>edit-20241104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4fa94c25-92ef-46a9-adf4-220335ddf022,g:59548894-11c8-44cc-a232-aa68c1c17873-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:edit="http://www.editasmedicine.com/20241104" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.editasmedicine.com/20241104">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20241104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20241104_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20241104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.editasmedicine.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>edit-20241104_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4fa94c25-92ef-46a9-adf4-220335ddf022,g:59548894-11c8-44cc-a232-aa68c1c17873-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="edit-20241104.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_9355eba9-0502-4914-80ac-957ef42639ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_b5eed01b-e40a-4ae2-8f80-780bd16e2160" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_9355eba9-0502-4914-80ac-957ef42639ad" xlink:to="loc_dei_DocumentInformationTable_b5eed01b-e40a-4ae2-8f80-780bd16e2160" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9cf2c0d6-c9b8-4427-9ee3-a9d14d5c92ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9355eba9-0502-4914-80ac-957ef42639ad" xlink:to="loc_dei_DocumentPeriodEndDate_9cf2c0d6-c9b8-4427-9ee3-a9d14d5c92ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>edit-20241104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4fa94c25-92ef-46a9-adf4-220335ddf022,g:59548894-11c8-44cc-a232-aa68c1c17873-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentPeriodEndDate_38c13634-564c-444d-9c86-f01030efd48b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_4afbb784-b1c9-4248-8359-60a3c87f91af_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ca475f7b-1dad-4f20-a7d9-aaeb8d9d2585_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6e910001-cc18-4ea6-babb-8b02196d6fd3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_402a9e64-ccec-48f9-a397-999c52ab430a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c526afec-009c-4193-8a7f-9420b1fd92d2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4e1635bb-3811-42ba-af8c-19cc0a6af0b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7a71ada9-c213-468a-91c9-214ecc29a958_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4491fc79-3191-4c6a-a782-aecb1f54d535_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d6eb90a1-9cde-469b-90a9-d29237351a2a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_31a6dbba-386a-46e1-a619-fd0e50318f08_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2717a9a1-b0f8-4d7e-b077-f6b02ad17274_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0a1c40a5-df80-4a70-88a6-d63230e07fc6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1c17d46d-b5b7-4510-9f99-0631a258703c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_cafd20a7-9dd3-45e1-ae3d-9352c2155b4f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_56369bd9-5eb8-46b3-ac37-ebfdab7faee3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b6f92f51-8a5b-4e5c-a9e4-dbce3ebd0eb2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_18e092e8-c70d-4510-9948-19daa4f31258_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b2a5b6af-75d2-49f6-aad5-1ab42fa32dec_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5d90de6b-9885-48d6-8402-77e39f5b0902_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_f01c02ac-6405-4ec5-95ca-219d48b63254_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c0446859-0e44-4d10-bad9-5e9d0e8bbfb2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ebba076b-4c91-4277-b8ae-1146c4dd7699_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_382a8d81-522b-420e-a9c9-2c76269cabff_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fd9fb468-aa63-44ef-840e-08be4828de77_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>edit-20241104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4fa94c25-92ef-46a9-adf4-220335ddf022,g:59548894-11c8-44cc-a232-aa68c1c17873-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="edit-20241104.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0e7c5b07-3f02-4ada-8254-57e3977292a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_DocumentType_0e7c5b07-3f02-4ada-8254-57e3977292a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1ac8189a-6022-4704-8f26-1abcaf2748c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_DocumentPeriodEndDate_1ac8189a-6022-4704-8f26-1abcaf2748c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0627a774-a9cf-4bfd-8050-5439f32f0a78" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityFileNumber_0627a774-a9cf-4bfd-8050-5439f32f0a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ab9cc61f-9f12-43f6-98f2-0b42656c653e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityRegistrantName_ab9cc61f-9f12-43f6-98f2-0b42656c653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2b285936-dd95-4fec-b630-b4bc53828dc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2b285936-dd95-4fec-b630-b4bc53828dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b4e68b58-1ca9-4130-a0e9-3cda235ecb3d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityTaxIdentificationNumber_b4e68b58-1ca9-4130-a0e9-3cda235ecb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c393f8ac-5432-4952-9f73-ccdd44eee164" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityAddressAddressLine1_c393f8ac-5432-4952-9f73-ccdd44eee164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_719b5f33-bd7b-4dab-834e-c4c97ef786d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityAddressCityOrTown_719b5f33-bd7b-4dab-834e-c4c97ef786d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3e51d8a9-afff-467d-b1c9-753ceb99f66e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityAddressStateOrProvince_3e51d8a9-afff-467d-b1c9-753ceb99f66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1de167a9-1b4a-4efe-88a3-441d3eb44a63" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityAddressPostalZipCode_1de167a9-1b4a-4efe-88a3-441d3eb44a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_31b9b0b8-f9a9-4130-8f9c-0c4ab6a60407" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_CityAreaCode_31b9b0b8-f9a9-4130-8f9c-0c4ab6a60407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0957d144-83b2-427c-b37b-8634c2c86d2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_LocalPhoneNumber_0957d144-83b2-427c-b37b-8634c2c86d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8af3f271-bb1d-4a70-8612-1a7b1c0d84cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_WrittenCommunications_8af3f271-bb1d-4a70-8612-1a7b1c0d84cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a315a302-1e73-4638-b018-b886f5b90fef" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_SolicitingMaterial_a315a302-1e73-4638-b018-b886f5b90fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_59580497-54eb-457d-980a-97f890765d0c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_PreCommencementTenderOffer_59580497-54eb-457d-980a-97f890765d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_94273dd0-4ff2-4dff-800b-eac8dfe42bed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_94273dd0-4ff2-4dff-800b-eac8dfe42bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f92986b8-08c6-4947-9d95-a8ca8c5541cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_Security12bTitle_f92986b8-08c6-4947-9d95-a8ca8c5541cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_57de59cd-7ff7-4cf8-8675-659965c8a37b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_TradingSymbol_57de59cd-7ff7-4cf8-8675-659965c8a37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b2faf1c4-c511-4589-8028-2eb34f5916f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_SecurityExchangeName_b2faf1c4-c511-4589-8028-2eb34f5916f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dbcee627-5e1f-46fd-95ab-d9fb6f4703e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityEmergingGrowthCompany_dbcee627-5e1f-46fd-95ab-d9fb6f4703e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d81e328d-a8a6-4cb4-b67d-d09c5dabe2ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_EntityCentralIndexKey_d81e328d-a8a6-4cb4-b67d-d09c5dabe2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a98cb12a-065b-44b8-94eb-dc5e0b45a488" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_AmendmentFlag_a98cb12a-065b-44b8-94eb-dc5e0b45a488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_b5eed01b-e40a-4ae2-8f80-780bd16e2160" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b1d74a10-dc1f-4510-8927-5241d973eab5" xlink:to="loc_dei_DocumentInformationTable_b5eed01b-e40a-4ae2-8f80-780bd16e2160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_9355eba9-0502-4914-80ac-957ef42639ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_b5eed01b-e40a-4ae2-8f80-780bd16e2160" xlink:to="loc_dei_DocumentInformationLineItems_9355eba9-0502-4914-80ac-957ef42639ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9cf2c0d6-c9b8-4427-9ee3-a9d14d5c92ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9355eba9-0502-4914-80ac-957ef42639ad" xlink:to="loc_dei_DocumentPeriodEndDate_9cf2c0d6-c9b8-4427-9ee3-a9d14d5c92ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M YRUX[Q#E)#=?-Z33S[EUY7SVJ1)$Q]](@I"1*1;MT]]-'C4J-$^ LU^(YN
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M/'@HEG42A$P@@B1\(Z)*A5QNO)T80(L6+?)Y\MQN3DH6GJ!"\)AAB(2\=E(
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M+-B6+=F626:4+;,DB\%B9F:TR&*6Q;9D2[*8++:8&8>AN^L_;]T^,U>CF='
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M[,;PAR0\N:Z$%W:6\-IQ$MF_2N3*R8J>B4HC[!_ -<;MTJ5+-9?- :1@I"H
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M';$; VM*>.23$C*_$Y[?T?SN'(F<.U#1,U%IQ!9I((?-%FG Z IB'SN E)P
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MGB(,*&X27C&H%BY<F%<J]-2IT]J@-J&%"SXGTRNS??&81#;/EO#,5@;$W&7
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M_O+3\FPAB(JNJNBGT[,/B&KB#$7?TXR7/>G$2=#B %*2"PJ:)I;0WH+P6%J
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MGU)7:1,W,U,E<F"=A%>,DM"$UR4TTH"D 0])J(<!2-VJQ6;T>T!"DQI)>,E
M"6^>)V$#DB*77=/8X@1J$?D5Y&70PX4]"74JB'WN %+E!D@8JN2G\?Y3ITZ3
M3ITZ:Q0GECF9]DXFOP0@QC=20AQ@1#&=]>LWR/[]!Y1^?.+$28VT4VJ:NQ,
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MFV^^J<Y7>F=1!8]H$N>4.8X'G1]V"9$LUI&>7!3-X>YPXB0(<0 IR04E@P+
MVX-!@R%WWWVQ+<5=5L5E>QH1Z2)T3D\.#+N9,V<ID(!GC%>4J%AEC1KY!<\<
M-)P>/7IJ$C<T!AHJ7KIX05(OG)'L\\>-%7Y(9,,LB4QK(^&>]Q@P4TW"G6\+
M?O#<;C7,;]PKX<%/27C1 (E\M%8DG!OMAU3Y<KQB+7A8J0)&?A\TIR"KDSF
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M<4GB64))T9"N7[]^"HSPB*+T:62(@JST35\+"-_$!8[2GSY]N@)6: @H;0P
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M(T!:MVZ]YE*24\CO!$4EHF\=?66XM]D/S D.I606'!&43"?:CF&-0PG:8KP
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M('WPP5K-26-/!!F=]TI[M]&\1*J"[=OWD<Y/,@L-2+DOH1JW:-%2]0CW8A
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MT,I?&-7L1:B>R1A!0B_@C-BW;Y_2"8G&L59!1FD]@/2@ J0&#1IHV>W" !)
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M4J3U'T0Z_%5DZ+,BBP>*[%LC<N6T2-H5D9S*4WS#V_]>U(CY))+P[KLK%)0
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M<>[9HV4!\T2BN+LXJQC?L2A3S7N3BP3E$&HO33=Q*'%W<\Z8MT0 2?:<X7S
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MT'U$M>E1"$C"V81^LG10_WX,>IT+6^^;K3E[CUZ .!2[=.F:5[0HR+Z*!<\
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M)\H!M6[+EJU*GT'I%4I1"^>*9*:(7#TK<FJ/R-I)(I,;B'3_BTA[ UY:_,
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M[JP97GY '?L.P!!KIY)]3_:BI>=B0!.UQ=,/!8\S0L0$IT7A9VOM#><,XQB
M1>2 J/RX<>,U HP^ &#@F(*F:*,&]EO+\[W^8AH6J'(_!YG#Q&] LYTX<9)&
MKP$4.%H*YG>B!RW%D/8*4'6A-+[TTDMYU0IC33OWZSU_F7+V(^ 4,$Q%/I@4
MY "AKUDOG)O<DVO6>,._WM"."[M3 1S02HG,  9IY(X3B\A_ITZ=-#+*V6=O
MHS^Y#V(-%OT@D;U&P22<)K $6+O*T O,2>43!Y"<%"LH!N@D>!_)@X%CW*Q9
ML[S*=O%0_$4I"Q2E;3K+)8UAP'NAJ %,&(1$*_R#?\^ECH)!L0&,,& J.GF8
M;P TH.PP[@$**"SK\2U5^=Y0CLCEDR+'MHKL6B*RN*O(R%H&O%!0P0"DAI\7
M>?VS(O4^'=S@>8T^[SV_U7<DW._ODC/Q><DVOWUX7C]9/7V83)GPIBK9IDV;
MJG)GK?A?@!*@%K!$SA?*'JH0T26,,, B<Y(_O'_G106[*=621J)MVK11Y<US
M )D (_8" -H"^J H/C8'A#W'OD)I QJ"JF[E %*^D/, A>OEEU_.BP#&ZYSZ
M#75^FS-*P0A N<V9 Q@A&-88T1AKT)&@_#)'1$V#!,]%#?][<K>Q]W%F842_
M_OKKONAZARAML+"S=>,YL^>+J %.!YQD@"(<39PQ]I57_MJ+P >18^0'IMS1
M#)[/_]HH?Q!SQKU#$0EHONQC=%UAD6M+Y65MH1<2K2%R \ "C,:C$I_5>S:J
MB6.&.Y3B)=P7K[SRBD9UH.*Q3JP7ZPQS@E'P+N7]_6MM618,^NVQ3]@OW*D4
MLP%PXX#D#-A[-5Z.17^#>9R>.,$ [A2N -C:,^C$29#B )*38L7/1\90A^L,
M7<HV^(MEF>O2* T_-89AJ7@%AZ7/V9$H%! ,&HP.<JJ@K@".2((N6P/(B+'6
MLKW*=FF71+;-%)GVJDC''XFT^*I(XW\V@.83!MA\/.!QB_?<AI^12+OOBO3]
MHT1&/2!79[20HTO'R/;UJ]6PH)\30-5ZAJUW&,.'_<2XZZY\P\@:1Q@$_*\U
ME/P# Y2_!]CE.;:74:R2PMDO_ [?@9&%T@8D!95SX@!2OI" C5><W[,&<KSO
M''O/X%P!N$.A@TH'2/+WT+$T+:)>>-X!)5"  1"QR,<HZCUOO?5Z.C)SQMFP
MYRO_7-UXMORCX/EB\*RBSEC0T5F;C,\ #  VK5$>Q._4KEU;>V&1DXINP^ N
M+AK!?8S3BGP?:,%$OLD/BD6UPINML3^JXE_GZ^_1NV^X*^W:HG-JUBS\/F78
M9_CO5.[J@FL>:]UI<[(L*(0^#RV28CP5W3;"27*+ TA.;BK^A.D=.W:JD8N7
MB3P>C$*;Z%[1S34KVT#A,'=$(*">H6PM.-JW[Z/R\:II'AL.B80,4#J\5N2]
M 2+CGQ09\%>13C\6:?8%#\R\_D\&V/RC&1\+;M0W0*G%5PP@^[Y(S]](QIC'
MY>+L]G)\Y5NR>O98&=._F[1H8@#%L[7EH2CUK23SE0@)WNQQC <,-3S'@",\
MZN2UX:G'D OB=QQ RI>#!P\I90BO.&>%,Q,/L%'8  #C4:<( Q[L/7OVJN.H
MH&!$8W"3HP,-#<\[!FE%[MWBAM]1%(O" R5]!VOPL\;H%B(T1)5Q'D&Q?.PQ
M+P\V*$!")(2[EX@)47LB?X55*+2"LXKU!K136(;V$SA\B*3%NB]>D,,/LBK:
M.7BS/<E99YULSA7.$M8)QT2B-LUUDASB )*3FXKUBD(AH0<19;*AVU'%AC ^
MB@SE@+<J*.I#,@^KG%#T&-50P^BW!-\;I9OOF2Y/P[M(/DBZ<$ADWSLB:\>(
MS&XL,K2Z2)OOB#3ZK$B#3WJ IN['@AL KL:?]4!2VV]+=N\_2]KH)^3RC):R
M;UI7>>?-GC)N:'_ITKF+U(U2D!(!_)1D8 !!"_0#(_CP#/Y=4$GY#B#E"V"#
M? @<"!C* --8E,\NR>!WO=YL7;5B)B")]RLHY*K06H"J9V/'CM7*>$0;*\L^
MKXCA18V\O%)T"I$=]A<@A+4'+#W]]-/FC-4*K'$YH-7+UZHK P<.TKQ'UJXH
M00\28>)^IBH@5=W0@U#1V!>V'41%S^7-1D4"X9*^GP7+W#?UZM53=@7%=W @
M,O<X;!TX<A)+<0#)28G%TNU(9"41F21/E -Y,R@9O'Y!=XY/QF$]I1BL*%8,
M*)*@X;93GM72!H+IYQ"M:G?MC,CY@R*;IWITNRX_%6GZ!0.2/A,%2/\0[*C_
M<0.^/F'&IR1BP%BXY^\D=UA-N3BAKNR?U4?6+YTC,Z9-D\Z=.BL%J:*;1Y9T
M &HQA*B.!]64ZHYP^/$B4P $X!#$[SB E"^<">; .F28_W@VKO8/#'CFD;4F
M+X>B!421"@IGF BPUSQSE3&^!RJ=J[+L\XH8-CI+)3YR7K@7B11016W&C!E:
M((!\11H[!Y7K9W^3_42QF 4+%F@OH>(,;YN/Q!I#R:.@# 5F^/M$"BL*O"?3
M\+?ZP.D$K8X"(S@/61] JJ/5.8FU.(#DI%3B[ZI]Z- AC21A?&'HUZU;5X&2
MS4V*1^)J91@6$&$<85SB9<1#"F6(2CR (XP C*F85.,ABI2;)9)E#.PCZT7>
M&R@R[@F1OG\2Z?0CD99?%6GX:8]R![ )&BPU_;P(.4D]?BD90^^3\V\UEB,+
MA\D',T?*A/Z=I5V3^E+GF2?ET8=J2<V[[TZ(9I+^P?O8? AH/ACI&.OT=N)_
M\3R3#$UT@QR5('[3 :1\P:-/\V>B2!BB1.WXEHJ(QECZ%_<<"?&L/Q7M"N8*
M\O]M:6CRD3#PB3)2^<LK<%,R6FFR#WNV #S0YXBH4\2%B#KW(NT- ,C0%0&9
M%)N@\$10=$5_L1_.+]1)"A)AA+-V-VNMP)_CSY.31@-J[H8Z=>KD]<YS.K!T
M:V&C1LP=9YP^6E LJ9Q(\V/THW4@.G$2:W$ R4FIQ0(DN-B4V*3L*;DS5 .B
MRS@>7FA(07GY*OOP5^#!0"*'@6IN4$?H6T'O'ZHGT=@O)M5X,-IH)$OA!DNW
M^V"4R+P6(J-KB73['P.2OB;2Y%\,2/JDR&O_$.QH^!F1YE\6:?/ODMWU5Y(Z
MH(9<'/V\'!S;6%8/;RDS!W:00=W:R1N-ZLFS3SVA\V0K(U7TVC%X'X /H)9\
M$JJ38;!1-A>O)A65'$"*G6 4'3]^0O,? 4GT!\-3;Y/%XPF2;)EE0!)Y)_2$
M(4*$,6V;.",V;Q-CCK.]9LT'>MZ[=^^NP(I]XNAV?\LK60W@)*>51K,T^J8,
M.?VON!/1,[ 5**1 A4NHK \]% R5U=]?C]8/K ]104MU9EV+$_*5 '$XN&@U
M@"%/94TJ:5+(B"(8%3W'E678PAR6]HB>Y'Q-GSY#:76LAVT&&PR[PHF3XL4!
M)"=E%G]U.X 27=7QHD$_0HF16Y+(/.=X#0PYP")&%71$$K?I3_'AASNT$=^E
M2Y?C4(TGX@$E*MNE0+<[(+)[D<BB]B)#:XAT^+X!25_WP$S0 (D*=]'J=N%F
M7Y;<-M^3[$Z_D&O]JLOI\:_+1_,&RYIYDV1TOV[2I/YK@?<4*N_@?8@<49&,
M_B_L<[K5DWOR_ONK-!?% :38";F/?#O-/'$FT*P2D&'+\\<32/MS(S#L67=Z
ML4 YQECF'-LS;!U)W)'D3!!IHMDFM$S6U]](M:+W>$4,YI*S!9#@[. TH@<:
MM#7FTT9PF%>B-'/FS)%^_?+;! 3Y+K9"88,&#:)M%J;*A@T;S7O<6(##+[P?
M>Q/:.7<"/83H7]>W;U^E"1))JJKK6]K!F:)*'0P+**Q$$7%$<7:H6&=I=:XP
M@Y-XB0-(3@(1/'UX>!<O7J*T$WIG4!T(1090PI/F[[1=T9=Q+(>MO$.IZOON
MNT_G (\W1AW-(Q<N7"0??;1?E6]*2FJ<Z0(4;PAY$:7S^T4V3Q&9U5ADV-TB
MO?]@@-(/1)I_1:0)S5\_+5+W'PW(^5AP8*G^/XDT^IQ(TR]*J--/)7/48Y(R
MO[,<6S1<E@YO+P-;OB+UGWY07GCL 7FBUGUR_[TUY>X:--J,3X5$6T##4NK8
MNUXAC;;:')*($<8:^YVQ<>,FC0PX@!1;P2#",*+G"8U.Z=D":*7P >\3KY+#
M_D'THWGSYC)ITB0M7(.'F[RC@M[M[.QL!7=$DK9NW:KEOZ';D7MGJ5C)#I;L
MM]ERS3B+,(1QI$$U)I^/R UG"V#D-X QC&F6S3GPSEIGS44*^AW91X U[FDB
M66^_O="<NX-Z[OP-@8L2UICW)-I%U44 '^7_J;QHU[FB^^TERO#W=,(9!E"V
MC6^))%*0 6<"8-E&C5S.D9-XBP-(3@(1E @& " )188A"5#BHB-4CC$#6  T
M8.PF:U3)&@$8UE!P,)KAI4,_G#3I+5FV;+E&CCR..WSJFRO>8"5:W0Z0E')6
MY.@&KW##\IX&*#44&?.(2+^_B'3^J4B+KWN A@B0 J4  %)=\ZSZGQ1I^#D)
MM_PWR>G^>\D<]J!<'/6<[.K[I"SO\(A,:O* #&SPF'2L_ZPT?/5%>>Z9IZ36
M _=+M1B7D?=SX $Z*&OV+L;2Q(D3-=]NRY:M&CEBOSN %%^ Q&#.,:*I^,B9
M:MFRI9ZSBJ!E\GOL$2K:<;9I'GOHT.$;'!Z<;[M?B!A#S9PZ=9KN*_87U$V_
M\5S1=UC0@[O>YOFP=\@A:MBPH19=($K ^8$Z24$&SE;!1JT8R !CC&7.PM"A
MPS3?->@RU3A%N+<!2>2YT9P8:A<4.O+@"FL@ZQ?6F'N=2!+Y,CC"B';Z=2!1
MQR#[.%7&X;]GF0_V/Y1$F"><:2+R[ ?..>M.!+GTO0"=."F_.(#D)!"Q-!B,
M@%.G3FN$9,N6+4HE(V>#W*3''W]<*Q1AS"2C!\TJ;*@_SS[[K%)!4(X8N>1I
MX5T\=>J4>IEMO@(7?\70!<QOYF2(I)X7N7C8 TI;IHLLZR$R]561(=6]QK(-
M/N6!)(#-J_\0P/B8]ZRZMTBDP6<EW/0K$FKU'Y+5_B=RI?/_RJGNM\M'/>^7
M][L_*].ZO2[]N[:5%HWJ2VURD\R\QM++;I4VAM(++[RHE9-&CQZCM!\,'J@>
M&$IXM-GO#B#%#R!9P4@E:9_\%$HLD_]%N77R%N)=& :CG_5^Z:67%:AAV&W>
MO.4&0QK#CG-.) DJ%B  )PGO3Y$6HE#^!JC)=C?:B+K-Y2-"@"$,98Y[D>J=
MQXX=5ZHV9ZN@P\@"3"(T% ::-FV:TEV#+N9B<T59!\ ,5,BY<^=JU ]@6UQ_
M)(0[@7N=")@%2IP]\DRY1\A?!'QY13J"*5->&0?S3.2(>Y8H*FO9OW]_I35"
MJ>,^H6"1U9.65N?$2;S% 20G@0L*C1X^7'!'CAS5Y-7APX=K'XM77GDE3TE8
MHX;+LB(H,N49-A>!:!@7O2T5BP& 1QL/) FF*'.\D"C8A$XLI13XJ9W&FIXO
MLG*@R/3Z!B35$&G_?9'6WQ9I01&'SQO ]%D#F#ZE ,<#31\+!C3QS#?^7:3[
MKR4TZ$XY-O Q63_P-9DSL(T,:5M/6KW\A-1^X$YYY*Z_2ZT:M\K]U6^3>^ZX
M3:I7,Z#FUEOE5NM-+N':^:M7L0<Q^O%F B(HI&$KU=E<,4!_P0(:%B!!F>K2
MI:M22H,&2#2O3%2 1)X 7O9X B3.$$83QBIG"DHO5"8*PW#NH-QQ#GE'&U7B
MG6^_/=^8]C=$+<]<\!Q+%X,>A$%-A!CJ;%$YA=;8YVX$*"U;MDRK(+[VVFOJ
M26>-N!>A'5%2W-*Q*L.]Z*_66=BY8GWJUZ^O>40 #X 13@?.T<T,8$NQ9-TQ
MHBFFP!YDKKA_@P:5Z"<,]V'#ALG"A0L5) ',2QK-*+A/;=-@(DF<&^;"ZD!T
M!]^ +JE,ZUW<L'>LW^G$GN9[^6Z<I=RSS#'[?_;LV4I-!%3>K#"&$R?Q$@>0
MG 0NME\2WD"\@B16XT7#&SYRY$@U:.@ATK1I,Z6HP$6O6;.F7J*)3C'Q)VFC
MV"P@0NG!I2?!=_CP$3)UZE1-WJ8:$EW7F8>$]H+E9HI<.2%R8IO([J4BZ\='
M:7>-1,8_(S+T;I%>?Q#I]!.15M_VP!*@IOXG//I=>4%2W7\RS_RB2-OO2JCS
MS^5BYS_(P<ZWR^;.]\OREC5DQNNWR8CG_RQ]GOD_Z?S,[=+JF;NDP9,UY;F'
M[I9:-6M(=6-,5M,<M^(-I?S^&G<:97VO&F[DAT'Q(,^(B!^EI,F'@#)%LT^\
MVQAQ!:E3>+2A!>'Y[-:MNP(D]G(0^PP/=I<N710@424-PR%1 !)GE>_$V*6R
M&+3:> EGB$@,<T$TCV^#CF/+K9/[B'."/!+6%>!B#5$/=%17AXS-A_0[9DH+
MFOBS-N( 2.+\0[4C<NX57[ETPYZQ[Y^6EJ;O#[BDCP[SZ)6+]^Y% !^5O#P
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M7<BS_?<A]S+OP?L04>3=,.[9_[PS# 'N=H 1@  C. CJ%'<K;1$ 60!_G!,
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MMW!^*M3@98-[/8X-@\L_<U6MXLJ/^3.K_U G='R)W>:E#G#J>11+K(\LL?-
M\NR79>6?_*[L05H7GH-SW.!6Q01&]B#MUPQ)NB>:95)_H[CGI)R[:>^4]5Q
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M&+,W)]_1V,.DX*$>/"I#'/<PY0U(5[NQZ\"YKX[5NU)9[@F?TYR11I\>^(<
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M:49*)=5#0%7?J;P!J:[?I^?GYN]XV:B>%<WN=>3=#)];?T<5%K_550JU+XF
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M07+;#;E[@6DF2XV7==Z>";SX7:EI[=3?3<\(J@GT16_S#%4]!$,"$KJ)@ 0
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M'>@B A(     ) 0D     $@(2     "0$)      ("$@ 0   $!"0 (   "
MA( $      D!"0     2 A(     ) 0D     $@(2     "0$)      ("$@
M 0   $!"0 (   " A( $      D!"0     2 A(     ) 0D     $@(2
M  "0$)      ("$@ 0   $!"0 (   " A( $      D!"0     2 A(
M) 0D     $@(2     "0$)      ("$@ 0   $!"0 (   " A( $      D!
M"0     2 A(     ) 0D     $@(2     "0$)      ("$@ 0   $!"0 (
M  " A( $      D!"0     2 A(     ) 0D     $@(2     "0$)
M("$@ 0   $!"0 (   " A( $      D!"0     2 A(     ) 0D     $@(
M2     "0$)      ("$@ 0   $!"0 (   " A( $      D!"0     2 A(
M    ) 0D     $@(2     "0$)      ("$@ 0   $!"0 (   " A( $
M  D!"0     2 A(     ) 0D     $@(2     "0$)      ("$@ 0   $!"
M0 (   " A( $      D!"0     2 A(     ) 0D     $@(2     "0_!^>
3CN;6DR2P:@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45762306119920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Editas Medicine, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4097528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Hurley Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-9000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EDIT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001650664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9%(<KCD#$[8WP/6EE.:M83\0E-]WAO\!4$L#!!0    ( "X\9%F?H!OPL0(
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( "X\9%D'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ +CQD67NMK][N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ +CQD69E<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  N
M/&196U3<S'T$  #K$0  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ +CQD69^@&_"Q @  X@P   T
M         ( !P P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  N/&19EXJ[
M',     3 @  "P              @ &<#P  7W)E;',O+G)E;'-02P$"% ,4
M    "  N/&19'#AEZC\!   \ @  #P              @ &%$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ +CQD620>FZ*M    ^ $  !H
M     ( !\1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ +CQD6660>9(9 0  SP,  !,              ( !UA(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="edit-20241104.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="edit-20241104.htm">edit-20241104.htm</File>
    <File>edit-20241104.xsd</File>
    <File>edit-20241104_def.xml</File>
    <File>edit-20241104_lab.xml</File>
    <File>edit-20241104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "edit-20241104.htm": {
   "nsprefix": "edit",
   "nsuri": "http://www.editasmedicine.com/20241104",
   "dts": {
    "inline": {
     "local": [
      "edit-20241104.htm"
     ]
    },
    "schema": {
     "local": [
      "edit-20241104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "edit-20241104_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "edit-20241104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "edit-20241104_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.editasmedicine.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20241104.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20241104.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001650664-24-000120-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001650664-24-000120-xbrl.zip
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M< Q(^H"'8^_=+1^ V+;9 [F)!S1Z=R3!&(%]%+R7=I3\?\RSJS"+?GQ(,:W
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M#@JQ04"U(^Y[,?WO3_3_F5+_/U!+ P04    "  N/&19^"#L'X "  !1"
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M@%N[DQ&D[02<&+)V._M\=;3K0FN[XAK&OSZ\VCR3KO[+]8=7_P=02P,$%
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M:+?&C7>S)Y#B_+X<[3U\T1[:_V\=[?T74$L#!!0    ( "X\9%D[5UK!C!P
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MZUCC"(B7.T/&X1TN'EZZH:1<OCZXZR:6DH!)-$CP%%$G]NDDM5N,NE"N'^8
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M+'9\5"BY\Y@,KOND8V\*DE8E.S\".W]*!@,1P##_YXB=!CP9)&@NY(J%3H-
M7>LCON-,E!:=(=+;S9A=WPT._@#.!#8*_WJT6;E*2>X;D?L%V =@HE&!38[&
M=Y&PN[M!V#C-7RJ\LMC97YNN=8W[/\U#+Z5=Q/J4WHF'J1D&QGWHX&5RIQ=I
M&>CQM[/;':+ZS"1K[ ;1'RM4HI_0+8TL]MN70IEDBUW!,\4:_\J1!#OFGK?5
M[C8%L55GFA4'*F9#I:M]>,ZY9.!KXI6$,"2M<!A(L%.9C.F8.8B],=8]N_#4
M15;&_+ONQ_6GZ,F A[.='O4U(4=XL8+'QVF,\L8,AC?Q:RX]"GX88_G4F,@1
MEAC%N<#FK,4-DX W1G>&#^-XI(UI:BA'/V18%?1$VDZAZBB?OM&V=P5<NHKI
MU6RZ .U"F>U13R7Q+"P*0F='T;IWZ<[B4N+MN4YB6H7&V,G<TY5!%*92-R+4
M_<S2ZS2S:#?U,R&TFIXF=(WHU*?=97U.3'>54/6PF4!6NH]3I_=PZEM]1T*-
M/,R1H&945,L4F1Y2IGTD[)R..31YJ]!SJ_.-%Z2O&T*; +*5'MM;^8L5+--!
MVO=!Y<%. ?X:(+ 0G\*>\%Q"-_[0U6F.ON*2M@CL.&D>0FT1RAJ[^==NC3]Z
MH>* 6KK^%8@L)9UY2I%I3>9,=@[1Y@>:Y30  1X#T+.#'D/_&'C +!!@OUCW
M/)IY@#[[S,-KO.OV]P#[Q@ >Q_EYNM.S:%K2'3 S^JJRM"0(@]$19B 9"C69
MM+E@YI28!:KU* Z.E[/&[.;F9H&@W@E9_)N^,+CR1:DK% P7""R2&@41R)=#
M.FO  P!@:P(Z=B;D,HC2VXXKGEE\E"V>L)?')@H\HYU]P0/3OQ6MBN^AO$8R
MNYAT1/@"_PST<^<"YV!'#K6YL+O=ECX) ?GH1OJB]O:A^0?O/]-1,\M08MJR
M:GI<#V0T2,W5@]+VBW>-2CQW]1"@:^KD<<<HJJ->/09TC0CN>)O/QZL'8)#Q
MCA&I@KQC6(B\=L>21Z'Z]YW[TAVG5H^)AG=#^F;1$!(C$AB#A[D6CZAKT5R,
M39\7Q>@"<=D?KR!J4*O@-*ID,"3[%RW=%1Q@N 1)'@_LS/2D_)%V2?8M>Y8>
MF^.[["ZSR<!0#&"*U,B9/;>G_<5KW):I#T8#O%\\$'U)$V.W%3-Q*+#NWLI=
MSZ3O\P/"AA$6F^H7JY^,EN42Y+N1DY62_A'%B2M-^;99P>+D1'.R&.GUZ#5D
M1Z?SJ0LZMU7WDYZH$%*>V4TJ^+[I&Q.C](G9]>7OBM,MA?79SBXT%=ZJ([M6
M4V$ZZI AF +3!?*M/ ()X'?>C)._^<U<87GQ>?69'/VYYM4ZEG$K)LZ$MKJU
M(#?GY$"5UA(NT)>>.?"(1+J9HBODQ)* EC8X%&[.1<EWCP/E-_&'<L(!9(,G
MKX#@ADKGM)O>ARH$<2\]ZMJ6-0^^!N:WLOXBLXB;0N]$^E*3DC )P->8[H^"
M2R)E 8X9Q\9T7-\PHJD'#_PL(Z:U74L]YW.OF-Q_D:F2E0H*ECU6"=/JDMX,
M+W&HL4:"\MZ3',,TZN[)JFAT(:]D CT]<F1D]<#2^GU@4+1MD$-@;QGKS&UL
MGC4VVA@FFG&S$,0?^!WD.4L?4U2P[2EZOBK,<Y&^P@6[%%)70C(L98#*;")J
M)LHL]9CQ]B:C'D#:5!9JIQE-D>?<3/"08,D+$(.<B;":;G2ZN9!(=3?LLWN8
MQL" F&/="#LE_7Z&/\+.NIO2L]X,=5,>1&0H_>FI^.PEP]1FOX<I0609HM-I
M=M:709Z0](?Z(:.W<]^9]I'Y=<P*U3P#9TRK.R$$!#*CPW%R95H.I> TK)Z'
ME^[O35"-$KP85N:+7&;1 I\#M0H*..)429#_9/V&-+")?Q(9IMQV23R0JQ^5
MT94V4UT1.:'L:5898%A)8!-RH&HOUS 'WD"42R<QM<-S>)S]IKF"/K(/4P,R
M9;FYG?DJ2L.TJ:(\I]ML45[\AGZ87:O\GP5D(<$NHSOK4'Z*2=.FG!.G5:LS
MY,& WN1+LKPMY&5M*U&FW:)U8-M.@ TAP8CGS=Y SJ>!8SI#/#1F0%XT^_QJ
MH]5G-@K1*(C(8)7#D/H *<3G+/I0I#?]+0+#M10W"&/4&AG7D)&)4HQNZ7'S
MDKZG!3R\+1FA1(LF\U/B2)Q.J6=#&.0@33?@XI[Q6B!ZEJB3D.3QFYD;EVY'
M8#A(C.:3(*>X)'ZA>E[JN@/G&9N8KX12L5($-X^"#,? \O#(5:2S*2=!#R(Y
M<UKB8A<K\C1[Y,FI<*3"E G P3+G)POI9'D976$BL#BU=']])?>[C4ZKYG9;
M]5ZWV;6=?:??Z38%=UM-FXMNZ^_FJR+<JSY;?TA'IF ,#X(#ASJGKW_XOI-/
M;:&Z8BX 2FC[>')Z>73!OL*_QZ=G'RUV>G:\G-Z+O)U&E\Z\ V CJ=5;%LQ%
M<?LM2Y_>W=WM<1_3PTV "BQPT$!@E JM-*B3BW;4T[XNY),OORK8<*$11BL9
ML3@P^#W@"7FA\_MZ_\YTMDR%; C6&:[3XZ-('*2_'(+.Q+/L QG0_/30X30P
M6K"8:Q%2:W,##P*-_MI(OFZWVJUW4/C%( -B-WVQD8M5DHN_Q.[\=\UFM=%J
M+OVZ5K67?K=J6KM>K>TO?W35M*N_:];:Y6)W:[&MM:;]A2A74R_P1P3FY:^O
M&J]F,CH/:LRF/*9TOFQH=VYH?72+@^<ER2P_:59Z^N:5ID4#5@Q]550Q]!%/
M(5"/3Q4-9>)E=L\O #QG&!Q>'SH/I:+)4".SR3!$G8;*G*7[W2T83N4(/G#'
M+PYRC<?@ON<*G)*L'H>L[A!;\[:NXP@!MNZ*;6/Z\Y8VO;@D^-[]\69I["Z@
M+"64*7#5V"X [<T/VGQ^TR&^KU"[;IOJZA^S>?QJ0R"L$DMW\>:L:"O)][F3
M;\MJ--HE!9<4O+,4;%L=NU92<$G!NTO!^U:MTRPB"6]LZYNX]B[9^M_FDA^F
MVQ-LPLHSVU_'4RSGV/(<C^3/$G]U"D[KRYJG+B7V^F9P6*AEBB=PFQVKW>C>
M3^ 6R#)X[EBJ62V[7F*IV%BR6S5@IGNZD"6:G@Q--3 RNZWMH>F13,F=4+/+
M6S?>2]$N@,2N4!T0W?[^AD2W O$_2C:L:V,^4RPUK>Y^I\12L;'4:H&>;918
M*CR6[.X6)=Y+\F8O%5:GS!>O/,2;?4 TM7C$V&Y9G?JF@GV78N,O%K,@9IK=
M>T8P2LP6&;/U6MNJMTO4/D/4VNV&5>]N:L*5!SV/?M"#-T$_Q!-_5E2Y!U9"
MN]U^NZFU6@Q9\XC>QO/":JMF@;PIL?J\L%JO-:U6JUNB]7FAU6ZVK+I=-+2^
MA$SO;Z97B*-\8;% Q/=/_EC7["WG*,X<+^E4*D_J;,\$R]X2T;^P8ZF]UL:2
M=D?5Y XBAUK)U _+@XX2326:'L&TM%K=VE;$W4LZBCK%NDW=#3RS)%]84F7#
M:C7N68>QH\'I'412R[*;]ZPT*)'T9.<$=6O_OF6E)9:>$$O-]A9YZ26YKB;3
M8S964Y[A3'1O?=/<WC(RO .(O8^^+A&[ XB]EXXO,;L+F*U9^QM7\Y;G.8\$
M_3,1+TSO^(&)1H6#P<NLHM]KUT%9VNN'NG8I9ZXDWV=/OLV65=LD!: DWY)\
MB[/K/;MK6^WN?DF_)?WN)OTVFE:CN4%B0)F7_<@F^Z0#O\5Z/)*.[E(B\8(/
M]Y%"?0W @ZL2['>_J_[E7JW:V3Q_94T8[&;0X'E@M;7K6%V^FOR"2IQ/LKFK
MC0=EZ!< YR56YRV)ZOX&48BGP>I+"/W]27\(M\)A57R MYWYO@JT21'A'=)1
MS.G&Q,>R+W;W\'J_;C7WL55!V06MZ)@"M[JY;]5;96Y5T3%5M^K-EM7NE#Q5
M<$QUFE:MW@6^VG8_M%_H%K7WZ]TBFBYK!^_/[+QZ7X#[,PM_3=\SNU?R0GC"
MP3LEIRZ8_, ]NL[]8BA$S$YCX3^WRR7+NR.+=W=DNU7=;W<?_]+ 9K7;7O[U
M_6\X[-1^T&+K3W+#X?S0!89! 6^[VO0NP_O'17850B?",0"R?]1UAKL%D'6O
MEGMQE/(R;X[CT=!B#OQDXI]$7G,/$!-9%&H"A7<EC,(43A*"#5[>&/?RCIKK
M[=8]NB*7Z1(E#1=GU\UZQ[(;]PR?E"D3#S[J4.$5-K)S^$C&W'MA[3OL[K[5
MV=_TRHD5Y6\[<$:Z@VBJ=SI6>^,+7!X132_!WM25D3R*1/R@OM<[2%\-T$&M
M]CW;6Q?(6GHDTBP>@IK=KF6W'N@#[J!V/A%]$8;"36\%IUIEIOH,?+X0;PL?
MJ1"/7UZ8VFXUK7KMGH5Q1=3:#Z/:XN&G7;/:[<Z+B]AH#1K%RKD:*@\<D^AG
M"MW$XQ>F3^T.WC#SC+K#/#=]VFAVK5IW 8?.I1',G#>2I[W.8>,3[(3.%%^_
M?GW7&6FZYJ</7M,*OPI7<HK:G@;7 J1#B*?8,7=F&L1.)VX\-1R/0QG%DGW@
M(5@8<4$6M=>V.V]9LV97:K;=*,BB'()4M:<A]=/K=O,0,!SSR!=NU5%^\;-M
M?NDI=PS_#&/?>___4$L! A0#%     @ +CQD66TFP/(O#P  0F@  !$
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@96QE87-E+FAT;5!+!08     !@ & ),!  ":1      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>edit-20241104_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="edit-20241104.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2024-11-04</startDate>
            <endDate>2024-11-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001650664</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Editas Medicine, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37687</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-4097528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">11 Hurley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">401-9000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EDIT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
